Temperature controlled camptothecin release from biodegradable magnetic PLGA microspheres
Source abstract
Abstract
Abstract Drug loaded magnetic microspheres (MMS) can be magnetically guided to a target area within the body, where the pharmaceutical agent is released passively. For a faster release, the microspheres have to be disintegrated actively, e.g., by an increase of the temperature of the MMS. In the here presented study, poly(lactic-co-glycolic) acid (PLGA) microspheres were prepared. Magnetic nanoparticles with high magnetic heating performance and the drug camptothecin were embedded into the PLGA matrix. Resulting microspheres were characterized by means of dynamic light scattering, scanning electron microscopy, magnetometry, magnetic calorimetry, and UV/Vis spectrophotometry for determination of the drug release as a function of time and temperature. The MMS diameter is about 1.5 µm and the MMS show a content of magnetic material of up to 16 wt% and a drug loading of about 0.5 wt%. The MMS have a specific heating power of 161 W/gMMS, which enables sufficient magnetic heating for enforced drug release from the MMS in tissue concentrations of 2% by mass. Depending on the applied temperatures and the used PLGA type, the loaded drug is released within hours to days and a temperature increase from 37 to 43 °C leads to a significant faster drug release. The principle of magnetically triggered drug release is demonstrated by magnetic hyperthermia induced release of a drug from the MMS.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery · Polymer Surface Interaction Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (24)
Show source-provided references
1. Current advances in polymer-based nanotheranostics for cancer treatment and diagnosis10.1021/am5036225 ↗
2. Camptothecin-based nanodrug delivery systems10.20892/j.issn.2095-3941.2017.0099 ↗
3. Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection
4. Prevention of K-Ras- and Pten-mediated intravaginal tumors by treatment with camptothecin-loaded PLGA nanoparticles10.1007/s13346-011-0038-y ↗
5. Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma10.1016/j.ijpharm.2015.01.002 ↗
6. Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells10.1021/bc800057g ↗
7. PLGA nanoparticles loaded cerebrolysin: studies on their preparation and investigation of the effect of storage and serum stability with reference to traumatic brain injury10.1007/s12035-015-9235-x ↗
8. Clinical experiences with magnetic drag targeting: A phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors
9. Magnetic particle hyperthermia-a promising tumour therapy?10.1088/0957-4484/25/45/452001 ↗
10. Polymer degradation and drug delivery in PLGA-based drug-polymer applications: A review of experiments and theories10.1002/jbm.b.33648 ↗
11. Influence of dextran coating on the magnetic behaviour of iron oxide nanoparticles10.1016/j.jmmm.2006.11.168 ↗
12. Ferrofluids of magnetic multicore nanoparticles for biomedical applications10.1016/j.jmmm.2009.02.073 ↗
13. Evaluation of PLGA microspheres as delivery system for antitumor agent-camptothecin10.1081/DDC-120021774 ↗
14. Use of hydrodynamic flow focusing for the generation of biodegradable camptothecin-loaded polymer microspheres10.1002/jps.21344 ↗
15. Production of monodispersed magnetic polymeric microspheres in a microfluidic chip and 3D simulation10.1007/s10404-015-1693-y ↗
16. Fabrication of a magnetite nanoparticle-loaded polymeric nanoplatform for magnetically guided drug delivery10.1007/s40242-013-2134-7 ↗
17. Magnetic field activated drug release system based on magnetic PLGA microspheres for chemo-thermal therapy10.1016/j.colsurfb.2015.10.014 ↗
18. Control of doxorubicin release from magnetic Poly(DL-lactide-co-glycolide) nanoparticles by application of a non-permanent magnetic field10.1007/s11051-015-3234-8 ↗
19. Magnetic multicore nanoparticles for hyperthermia-influence of particle immobilization in tumour tissue on magnetic properties10.1088/0957-4484/22/26/265102 ↗
20. Development of a coflowing device for the size-controlled preparation of magnetic-polymeric microspheres as embolization agents in magnetic resonance navigation technology10.1021/acsbiomaterials.7b00839 ↗
21. Magnetic nanoparticles adapted for specific biomedical applications
22. Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly (lactic acid)-co-(glycolic acid)10.1002/pi.1697 ↗
23. Avgoustakis · 2008 · 2259
24. Effect of drug type on the degradation rate of PLGA matrices10.1016/j.ejpb.2006.06.009 ↗